YU15795A - Postupak za dobijanje kulture virusa hepatitisa a - Google Patents

Postupak za dobijanje kulture virusa hepatitisa a

Info

Publication number
YU15795A
YU15795A YU15795A YU15795A YU15795A YU 15795 A YU15795 A YU 15795A YU 15795 A YU15795 A YU 15795A YU 15795 A YU15795 A YU 15795A YU 15795 A YU15795 A YU 15795A
Authority
YU
Yugoslavia
Prior art keywords
virus
microcarrier
culture
bioreactors
provides
Prior art date
Application number
YU15795A
Other languages
English (en)
Inventor
F.S. Leu
D. Seifert
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of YU15795A publication Critical patent/YU15795A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

POSTUPAK ZA DOBIJANJE KULTURE VIRUSA HEPATITISA A je postupak na baži mikronosača za dobijanje virusnih vakcina, od kojih je jedan primer virus hepatitisa A (HAV) koji se sastoji od jednog agregiranog mikronosačkog sistema od staklom obloženih polistirolnih mikronosača i MRC-5 ćelija što daje stabilnu okolinu za razmnožavanje virusa čak preko produženih infakcionih perioda. Mikronosački agregati obrazovani prema ovom postupku eliminišu otpadanje ćelija sa granula tokom dugih kultivacija što se događa u drugim sistemima, omogućujući visoku produktivnost virusa u mikronosačkoj kulturi. Metodologija je primenljiva tamo gde se proizvodnja virusa može poboljšati kreiranjem stabilne kulture tokom produženog infekcionog perioda. Upotrebljavaju se bioreaktori koji se mogu menjati po veličini koji se mešaju umesto višestrukih paralelnih bioreaktora sa stacionarnom površinom. Ovaj agregirani mikronosački postupak eliminiše ograničenja kapaciteta bioreaktora sa stacionarnom površinom, on štiti ćelije na kojima je virus kultivisan od smicanja, obezbedjuje povećaneinterakcije ćelije na ćeliju, obezbeđuje stabilnu sredinu za razvijanje virusa, obezbeđuje slobodan prostor za konvektivni transport hranljivih materijala kroz agregate, i obezbeđuje direktan postupak za sakupljanje virusnog lizata za kasniji tok proizvodnje.
YU15795A 1994-03-08 1995-03-08 Postupak za dobijanje kulture virusa hepatitisa a YU15795A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20816294A 1994-03-08 1994-03-08

Publications (1)

Publication Number Publication Date
YU15795A true YU15795A (sh) 1997-08-22

Family

ID=22773456

Family Applications (1)

Application Number Title Priority Date Filing Date
YU15795A YU15795A (sh) 1994-03-08 1995-03-08 Postupak za dobijanje kulture virusa hepatitisa a

Country Status (10)

Country Link
US (1) US6194210B1 (sh)
CN (1) CN1147833A (sh)
AU (1) AU1973795A (sh)
BR (1) BR9507333A (sh)
CZ (1) CZ258996A3 (sh)
FI (1) FI963514A (sh)
HR (1) HRP950097A2 (sh)
RO (1) RO115176B1 (sh)
WO (1) WO1995024468A1 (sh)
YU (1) YU15795A (sh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
DK0981601T3 (da) * 1997-01-31 2007-01-15 Schering Corp Fremgangsmåder til dyrkning af celler og opformering af vira
US6146891A (en) 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
US6168944B1 (en) 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
KR100537718B1 (ko) * 1999-01-29 2005-12-20 씨제이 주식회사 에이형 간염 바이러스 백신 항원의 제조방법
WO2001014517A1 (fr) * 1999-08-20 2001-03-01 Japan Science And Technology Corporation Procede et appareil de proliferation du virus de l'hepatite
IL157304A0 (en) * 2001-03-16 2004-02-19 Oncolytics Biotech Inc Method of extracting virus from cell culture
DE10145568A1 (de) * 2001-09-14 2003-04-03 Knoell Hans Forschung Ev Verfahren zur Kultivierung und Analyse mikrobieller Einzelzellkulturen
US6855535B2 (en) 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
BR0309659A (pt) 2002-04-30 2005-02-22 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
DE102004049290A1 (de) 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
KR20070104339A (ko) 2004-11-03 2007-10-25 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터의 생산과 정제를 위한 신규한 방법
AR078253A1 (es) * 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
SI2513288T1 (sl) 2009-12-16 2014-08-29 Vivabiocell Spa Naprava za neprekinjeno kultivacijo
CN102000326B (zh) * 2010-11-25 2013-10-16 成都康华生物制品有限公司 一种生产人用狂犬疫苗的方法
CN102058882B (zh) * 2010-12-28 2012-12-26 深圳康泰生物制品股份有限公司 一种制备甲型肝炎灭活疫苗的方法
KR101983980B1 (ko) * 2011-02-17 2019-05-30 베링거잉겔하임베트메디카게엠베하 Ｐｒｒｓｖ의 상업적 규모의 제조 방법
CN102492659A (zh) * 2011-11-14 2012-06-13 成都康华生物制品有限公司 一种疫苗生产用甲肝病毒的生产方法
CN105073130A (zh) 2013-03-15 2015-11-18 勃林格殷格翰动物保健公司 猪生殖与呼吸综合征病毒、组合物、疫苗及使用方法
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
CN106754651B (zh) * 2017-02-28 2020-05-12 浙江普康生物技术股份有限公司 一种人二倍体细胞微载体培养有效传代的方法
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105011A (en) 1961-06-19 1963-09-24 Parke Davis & Co Antigens and process of producing same
US3976547A (en) 1972-01-24 1976-08-24 Merck & Co., Inc. Cell and vaccine production
US3994870A (en) 1974-01-31 1976-11-30 The Community Blood Council Of Greater New York, Inc. Purification of hepatitis B surface antigen
US4029764A (en) 1974-12-09 1977-06-14 Merck & Co., Inc. Hepatitis A antigen
US4031203A (en) 1974-12-09 1977-06-21 Merck & Co., Inc. Hepatitis A antigen
US4017601A (en) 1975-10-16 1977-04-12 Merck & Co., Inc. Hepatitis A antigen
FR2398504A1 (fr) 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4296204A (en) 1978-01-25 1981-10-20 Merck & Co., Inc. Use of motionless mixer as cell culture propagator
DE2829741A1 (de) 1978-07-06 1980-01-24 Behringwerke Ag Verfahren zur gewinnung des hepatitis a-virus
US4164566A (en) 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
JPS55147227A (en) * 1979-05-04 1980-11-17 Handai Biseibutsubiyou Kenkyukai Preparrtion of attenuated live mumps vaccine
US5021348A (en) 1979-09-04 1991-06-04 Merck & Co., Inc. Attenuated hepatitis A virus
CA1164799A (en) 1979-09-04 1984-04-03 Paula A. Giesa Cell culture of hepatitis a virus
US4415670A (en) 1980-07-07 1983-11-15 Merck & Co., Inc. Motionless mixer as cell culture propagator
US4301249A (en) 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
DE3135599A1 (de) 1981-09-09 1983-08-25 Flehmig Bertram An menschliche fibroblastenzellen adaptierte hepatitis-a-viren
US4721675A (en) * 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
US4412002A (en) 1982-02-26 1983-10-25 Merck & Co., Inc. Process for preparing hepatitis A virus
US4448884A (en) * 1982-03-03 1984-05-15 Kms Fusion, Inc. Glass-surface microcarrier for growth of cell cultures
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US4894228A (en) 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4532215A (en) 1982-04-07 1985-07-30 The United States Of America As Represented By The Department Of Health And Human Services Isolation of hepatitis A virus strain HM-175
US4620978A (en) 1982-04-07 1986-11-04 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis A virus purified and triply cloned
US4636469A (en) 1982-04-07 1987-01-13 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Isolation of hepatitis A virus strain HM-175
US4605623A (en) 1982-11-08 1986-08-12 Malette William Graham Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture
JPS61500053A (ja) 1983-09-30 1986-01-16 マサチユ−セツツ　インステイチユ−ト　オブ　テクノロジ− Ａ肝炎ウィルス配列順を表すｃＤＮＡの生成
US4614793A (en) 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
US4564532A (en) * 1985-01-07 1986-01-14 Kms Fusion, Inc. Glass-surface microcarrier for anchorage-dependent cell cultivation
US4636385A (en) * 1985-02-15 1987-01-13 The Wistar Institute Of Anatomy & Biology Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection
US4683294A (en) 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
CA1324094C (en) 1985-04-03 1993-11-09 Dino Dina Hepatitis a virus vaccines
US4783407A (en) 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
US5160490A (en) 1986-04-18 1992-11-03 Marrow-Tech Incorporated Three-dimensional cell and tissue culture apparatus
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
SU1469856A1 (ru) 1986-07-31 1990-09-30 Институт биоорганической химии им.М.М.Шемякина Способ конструировани рекомбинантной плазмидной ДНК, кодирующей синтез полипептидных субстанций против гепатита А
US4975377A (en) 1987-05-14 1990-12-04 Key Marc E Cell growth chambers and method of use thereof
HUT48505A (en) 1987-06-29 1989-06-28 Attila Zsiger Wood-working-industrial auger drill
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5004688A (en) 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
JPH0761955B2 (ja) 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
JPH0751513B2 (ja) 1988-04-28 1995-06-05 国立予防衛生研究所長 Ａ型肝炎ワクチン
US5268292A (en) 1988-06-27 1993-12-07 Robertson Betty H Reproducible generation of high yields of hepatitis A virus by cell culture
CN1022331C (zh) 1989-08-17 1993-10-06 浙江省医学科学院 甲型肝炎减毒活疫苗毒种及其制造方法
CA2047041A1 (en) 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids
DZ1706A1 (fr) * 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
JP3523646B2 (ja) 1992-09-18 2004-04-26 スミスクライン・ビーチヤム・バイオロジカルズ・エス・エイ Ａ型肝炎ワクチン
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process

Also Published As

Publication number Publication date
HRP950097A2 (en) 1997-06-30
FI963514A0 (fi) 1996-09-06
CZ258996A3 (en) 1997-06-11
AU1973795A (en) 1995-09-25
US6194210B1 (en) 2001-02-27
WO1995024468A1 (en) 1995-09-14
CN1147833A (zh) 1997-04-16
BR9507333A (pt) 1997-09-16
RO115176B1 (ro) 1999-11-30
FI963514A (fi) 1996-11-06

Similar Documents

Publication Publication Date Title
YU15795A (sh) Postupak za dobijanje kulture virusa hepatitisa a
Chen et al. Investigations into the metabolism of two-dimensional colony and suspended microcarrier cultures of human embryonic stem cells in serum-free media
Li et al. Three-dimensional spheroid culture of human umbilical cord mesenchymal stem cells promotes cell yield and stemness maintenance
Montagnon et al. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine.
Montagnon et al. Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine. Promising results.
Roberts et al. Scale-up of human embryonic stem cell culture using a hollow fibre bioreactor
EA200200604A1 (ru) Производство вакцин
KR20120038531A (ko) 연속 세포 배양에서 목적 폴리펩티드 또는 바이러스를 생산하는 방법
ES8104405A1 (es) Procedimiento para preparar una vacuna de virus de gripe
Fang et al. Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects
Macieira-Coelho et al. The transition from primary culture to spontaneous immortalization in mouse fibroblast populations
Du et al. Human iPS cell-derived fibroblast-like cells as feeder layers for iPS cell derivation and expansion
Clark et al. Serum supplements and serum-free media: applicability for microcarrier culture of animal cells.
JP6933643B2 (ja) Ｍｄｃｋ細胞の培養方法
Zhang et al. Suspended cell lines for inactivated virus vaccine production
CA2316739C (en) Preparation of cells for production of biologicals
FI98377B (fi) Adherentisti sitoutuneita soluja sisältävä matriisi ja menetelmä virus/virusantigeenin tuottamiseksi
Van Wezel Present state and developments in the production of inactivated poliomyelitis vaccine.
FR2857671B1 (fr) Nouveau procede de culture de keratinocytes et ses applications
RIa et al. Influenza virus reproduction in the MDCK cells adapted to growth in serum-free Hybris-2 medium
Shen et al. DEVELOPMENT OF SUSPENSION ADAPTED VERO CELL CULTURE PROCESS FOR PRODUCTION OF VIRUSES
Varani et al. Human diploid fibroblast growth on polystyrene microcarriers in aggregates
El Wajgali et al. Influence of operating parameters of a settling-based perfusion process on expansion of VERO cells attached on microcarriers
EP1211309A4 (en) METHOD AND DEVICE FOR PROPAGING HEPATITISVIRUS
Fang Shen et al. Development of suspensions adapted Vero cell culture process for production of viruses